Transjugular Intrahepatic Portosystemic Shunt Benefits for Hepatic Sinusoidal Obstruction Syndrome Associated with Consumption of Gynura Segetum: a Propensity Score-Matched Analysis
- PMID: 37225971
- DOI: 10.1007/s00270-023-03451-9
Transjugular Intrahepatic Portosystemic Shunt Benefits for Hepatic Sinusoidal Obstruction Syndrome Associated with Consumption of Gynura Segetum: a Propensity Score-Matched Analysis
Abstract
Purpose: Pyrrolidine alkaloids-related hepatic sinusoidal obstruction syndrome (PA-HSOS) is associated with a high mortality rate without standardized therapy. The efficacy of transjugular intrahepatic portosystemic shunts (TIPS) remains controversial. The study aimed to explore the risk factors influencing the clinical response in patients with PA-HSOS related to Gynura segetum (GS) to assess the disease prognosis at an early stage and to evaluate the efficacy of TIPS in these patients.
Methods: This study retrospectively enrolled patients diagnosed with PA-HSOS between January 2014 and June 2021 with a clear history of exposure to GS. Univariate and multivariate logistic regression analyses were used to evaluate the risk factors influencing the clinical response in patients with PA-HSOS. Propensity score matched (PSM) was performed to compensate for differences in baseline characteristics between patients with and without TIPS. The primary outcome was the clinical response defined as the disappearance of ascites with normal total bilirubin levels and/or a reduction of elevated transaminase levels < 50% within 2 weeks.
Results: A total of 67 patients were identified in our cohort with a clinical response rate of 58.2%. Of these, thirteen patients were assigned to the TIPS group and 54 to the conservative treatment group. Logistic regression analysis revealed that TIPS treatment (P = 0.047), serum globulin levels (P = 0.043), and prothrombin time (P = 0.001) were independent factors influencing clinical response. After PSM, there was a higher long-term survival rate of patients (92.3% vs. 51.3%, P = 0.021) and a shorter hospital stay (P = 0.043), but a high trend in hospital costs (P = 0.070) in the TIPS group. The 6-month survival probability in patients undergoing TIPS therapy was more than ninefold higher than in patients without receiving that treatment [hazard ratio (95% CI) = 9.304 (4.250, 13.262), P < 0.05].
Conclusions: TIPS therapy may be an effective treatment option for patients with GS-related PA-HSOS.
Keywords: Gynura segetum; Hepatic sinusoidal obstruction syndrome; Propensity score-matched analysis; Transjugular intrahepatic portosystemic shunt.
© 2023. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
Similar articles
-
Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt.Hepatol Int. 2021 Jun;15(3):720-729. doi: 10.1007/s12072-020-10126-x. Epub 2021 Jan 28. Hepatol Int. 2021. PMID: 33507485
-
Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.BMC Gastroenterol. 2021 Jan 10;21(1):26. doi: 10.1186/s12876-021-01599-7. BMC Gastroenterol. 2021. PMID: 33423668 Free PMC article.
-
Transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome.World J Gastroenterol. 2020 Jun 28;26(24):3472-3483. doi: 10.3748/wjg.v26.i24.3472. World J Gastroenterol. 2020. PMID: 32655270 Free PMC article.
-
Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.J Gastroenterol Hepatol. 2019 Apr;34(4):634-642. doi: 10.1111/jgh.14612. Epub 2019 Feb 21. J Gastroenterol Hepatol. 2019. PMID: 30669184 Review.
-
Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.World J Gastroenterol. 2019 Jul 28;25(28):3753-3763. doi: 10.3748/wjg.v25.i28.3753. World J Gastroenterol. 2019. PMID: 31391770 Free PMC article. Review.
Cited by
-
Efficacy and safety of transjugular intrahepatic portosystemic shunt in hepatic sinusoidal obstruction syndrome: systematic review and meta-analysis.Front Med (Lausanne). 2025 Aug 13;12:1625825. doi: 10.3389/fmed.2025.1625825. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40880758 Free PMC article.
-
Drug-induced hepatic sinusoidal obstruction syndrome: current advances and future perspectives.Arch Toxicol. 2025 Mar;99(3):835-850. doi: 10.1007/s00204-024-03950-9. Epub 2024 Dec 24. Arch Toxicol. 2025. PMID: 39718593 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous